E-viri
PDF
Recenzirano
Odprti dostop
-
Payne, Rebecca P.; Austin, James A.; Skelly, Donal T.; Meardon, Naomi; Faustini, Sian; Al-Taei, Saly; Moore, Shona C.; Hering, Luisa M.; Angyal, Adrienn; Brown, Rebecca; Nicols, Alexander R.; Gillson, Natalie; Dobson, Susan L.; Amini, Ali; Supasa, Piyada; Cross, Andrew; Bridges-Webb, Alice; Linder, Aline; Altmann, Thomas; Whitham, Rachel; Phillips, Eloise; Hargreaves, Alexander; Shields, Adrian; Foulkes, Sarah; Johnson, Sile; Wootton, Daniel G.; Conlon, Christopher P.; Matthews, Philippa C.; Frater, John; Deeks, Alexandra S.; Pollard, Andrew J.; Brown, Anthony; Rowland-Jones, Sarah L.; Mongkolsapaya, Juthathip; Hopkins, Susan; Dold, Christina; Richter, Alex; Carroll, Miles; Screaton, Gavin; de Silva, Thushan I.; Turtle, Lance; Klenerman, Paul; Dunachie, Susanna; Abuelgasim, Hibatullah; Adland, Emily; Adlou, Syed; Akther, Hossain Delowar; Ansari, M. Azim; Arancibia-Cárcamo, Carolina V.; Bayley, Martin; Brown, Helen; Chand, Meera; Chawla, Anu; Chinnakannan, Senthil; Cutteridge, Joseph; de Lara, Catherine; Denly, Lucy; Diffey, Ben; Dimitriadis, Stavros; Drake, Thomas M.; Donnison, Timothy; Dupont, Maeva; Gardiner, Siobhan; Gilbert-Jarmillo, Javier; Goulder, Philip; Hackstein, Carl-Philipp; Hambleton, Sophie; Haniffa, Muzlifah; Haworth, Jenny; Holmes, Jennifer; Jämsén, Anni; Johnson, Sile; Jones, Chris; Kelly, Sinead; Kirk, Rosemary; Knight, Michael L.; Lawrie, Allan; Lee, Lian; Lett, Lauren; Lim, Nicholas; Mentzer, Alexander J.; O’Donnell, Denise; Payne, Brendan A.I.; Provine, Nicholas; Robinson, Nichola; Romaniuk, Leigh; Simmons, Beatrice; Spegarova, Jarmila S.; Stephenson, Emily; Subramaniam, Kris; Travis, Simon; Tucker, Stephanie; Watson, Adam; Watson, Lisa; Weeks, Esme; Wilson, Robert; Wood, Steven; Wright, Rachel; Xiao, Huiyuan; Zawia, Amira A.T.
Cell, 11/2021, Letnik: 184, Številka: 23Journal Article
Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was introduced in the United Kingdom to accelerate population coverage with a single dose. At this time, trial data were lacking, and we addressed this in a study of United Kingdom healthcare workers. The first vaccine dose induced protection from infection from the circulating alpha (B.1.1.7) variant over several weeks. In a substudy of 589 individuals, we show that this single dose induces severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody (NAb) responses and a sustained B and T cell response to the spike protein. NAb levels were higher after the extended dosing interval (6–14 weeks) compared with the conventional 3- to 4-week regimen, accompanied by enrichment of CD4+ T cells expressing interleukin-2 (IL-2). Prior SARS-CoV-2 infection amplified and accelerated the response. These data on dynamic cellular and humoral responses indicate that extension of the dosing interval is an effective immunogenic protocol. Display omitted •BNT162b2 vaccine with an extended interval between doses is highly protective•Antibody levels were higher after the extended regimen compared with the short regimen•The extended regimen enriches for virus-specific CD4+ T cells expressing IL-2•Antibody levels wane after each dose, but B and T cell pools are maintained After giving a primary dose, delaying administration of a second dose of BNT162b2 COVID-19 vaccine up to 6–14 weeks continues to provide strong protection and contributes to favorable antibody, B cell, and T cell responses.
